JP2010505897A - インフルエンザターゲット - Google Patents
インフルエンザターゲット Download PDFInfo
- Publication number
- JP2010505897A JP2010505897A JP2009531778A JP2009531778A JP2010505897A JP 2010505897 A JP2010505897 A JP 2010505897A JP 2009531778 A JP2009531778 A JP 2009531778A JP 2009531778 A JP2009531778 A JP 2009531778A JP 2010505897 A JP2010505897 A JP 2010505897A
- Authority
- JP
- Japan
- Prior art keywords
- kinase
- influenza virus
- gene
- pharmaceutical composition
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85065106P | 2006-10-11 | 2006-10-11 | |
| PCT/EP2007/008852 WO2008043561A2 (en) | 2006-10-11 | 2007-10-11 | Influenza targets |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010505897A true JP2010505897A (ja) | 2010-02-25 |
| JP2010505897A5 JP2010505897A5 (cg-RX-API-DMAC7.html) | 2010-10-21 |
Family
ID=39203225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009531778A Pending JP2010505897A (ja) | 2006-10-11 | 2007-10-11 | インフルエンザターゲット |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110150897A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2087110A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010505897A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007306542B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2666185A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG166778A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008043561A2 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023549500A (ja) * | 2020-11-13 | 2023-11-27 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 凝固第V因子(F5)iRNA組成物およびその使用方法 |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| AU2003225410A1 (en) | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| EA200900741A1 (ru) | 2006-11-27 | 2010-04-30 | Айзис Фармасьютикалз, Инк. | Способы лечения гиперхолестеринемии |
| AR066984A1 (es) | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
| US8435510B2 (en) * | 2007-08-08 | 2013-05-07 | Sutter West Bay Hospitals | Platelet derived growth factor receptor supports cytomegalovirus infectivity |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| NZ584793A (en) | 2007-10-26 | 2012-05-25 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| EP2276455A2 (fr) * | 2008-04-22 | 2011-01-26 | Centre National de la Recherche Scientifique | Utilisation d'inhibiteurs de kif13a et d'ap-1 pour inhiber la mélanogénèse |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| EP2405921A4 (en) * | 2009-01-26 | 2013-05-22 | Protiva Biotherapeutics Inc | COMPOSITIONS AND METHODS FOR VAPORING APOLIPOPROTIEN C-III EXPRESSION |
| WO2010111468A2 (en) * | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
| CN102459595A (zh) | 2009-04-24 | 2012-05-16 | 普罗森那技术公司 | 用于治疗dmd的包含肌苷的寡核苷酸 |
| WO2011071535A2 (en) * | 2009-12-11 | 2011-06-16 | Mount Sinai School Of Medicine Of New York University | Compositions and methods for inhibiting human host cell factors required for influenza virus replication |
| JP2013515697A (ja) * | 2009-12-23 | 2013-05-09 | マックスプランク−ゲセルシャフト・ツール・フェーデルング・デル・ヴィッセンシャフテン・エー・ファウ | インフルエンザ標的 |
| EP2563921B1 (en) * | 2010-04-30 | 2016-11-23 | Cellectis | Method for modulating double-strand break-induced homologous recombination |
| CN109112126B (zh) * | 2010-06-23 | 2024-06-14 | 库尔纳公司 | 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病 |
| EP2426216A1 (en) * | 2010-09-01 | 2012-03-07 | Institut Gustave Roussy (IGR) | Prognostic and/or predictive biomarkers and biological applications thereof |
| GB201018147D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Method of treatment |
| EP2633052B1 (en) * | 2010-10-27 | 2018-04-11 | CuRNA, Inc. | Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1 |
| EP2446883A1 (en) * | 2010-10-30 | 2012-05-02 | University College Cork-National University of Ireland, Cork | Treatment of inflammation |
| WO2012075114A2 (en) * | 2010-12-01 | 2012-06-07 | Ablitech, Inc. | Nucleic acid-polymer conjugates and uses thereof |
| WO2012122645A1 (en) * | 2011-03-11 | 2012-09-20 | Sarissa Inc. | Methods of treating cancer by inhibition of dna repair proteins |
| US20140227289A1 (en) * | 2011-05-13 | 2014-08-14 | Stephen Michael Cohen | Compounds and methods for treating insulin resistance syndrome |
| WO2013048345A1 (en) * | 2011-09-28 | 2013-04-04 | Agency For Science, Technology And Research | Methods and pharmaceutical compositions for treating cancer |
| CA2862628C (en) | 2012-01-27 | 2021-08-24 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| CA2866392C (en) | 2012-03-30 | 2023-10-24 | Washington University | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
| WO2013157215A1 (ja) * | 2012-04-17 | 2013-10-24 | 国立大学法人山口大学 | 子宮体がん発症感受性の判定方法 |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| BR112015022156A2 (pt) | 2013-03-14 | 2017-11-14 | Isis Pharmaceuticals Inc | composições e métodos para modular a expressão de tau |
| TWI702046B (zh) | 2013-07-19 | 2020-08-21 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| EP2853596A1 (en) | 2013-09-30 | 2015-04-01 | IKBT (Institut für Klinische Biomedizinische Forschung Thurgau) | Protein phosphatase inhibitor |
| US20160333346A1 (en) | 2014-01-17 | 2016-11-17 | Kyowa Hakko Kirin Co., Ltd. | Nucleic acid capable of inhibiting expression of beta-2gpi |
| JP6663149B2 (ja) * | 2014-07-04 | 2020-03-11 | 国立大学法人高知大学 | 膵がん細胞浸潤転移阻害剤 |
| WO2016081444A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| US20190071668A1 (en) * | 2015-07-08 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of cancer using slncr isoforms |
| CA3005131A1 (en) * | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of tuberous sclerosis complex |
| PT109454A (pt) * | 2016-06-14 | 2017-12-14 | Phyzat Biopharmaceuticals Lda | Ácidos nucleicos de interferência e composições que os compreendem |
| MD3519572T2 (ro) | 2016-09-29 | 2024-03-31 | Biogen Ma Inc | Compuși și procedee de reducere a expresiei Tau |
| TW201903149A (zh) | 2017-05-31 | 2019-01-16 | 日商協和醱酵麒麟有限公司 | 抑制apcs之表現的核酸 |
| TN2019000308A1 (en) | 2017-07-06 | 2021-05-07 | Arrowhead Pharmaceuticals Inc | RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE |
| CN111212909A (zh) * | 2017-10-17 | 2020-05-29 | 箭头药业股份有限公司 | 用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物 |
| EP3710587A1 (en) * | 2017-11-16 | 2020-09-23 | Alnylam Pharmaceuticals, Inc. | Kisspeptin 1 (kiss1) irna compositions and methods of use thereof |
| MY207352A (en) * | 2018-03-21 | 2025-02-21 | Regeneron Pharma | 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
| EP3689896A1 (en) * | 2019-01-31 | 2020-08-05 | Universität Heidelberg | Grk2 modulating mirnas |
| JP7574215B2 (ja) | 2019-04-29 | 2024-10-28 | ソレント セラピューティクス,エルエルシー | MRGX2の阻害薬である3-アミノ-4H-ベンゾ[e][1,2,4]チアジアジン1,1-ジオキシド誘導体 |
| JP2022535717A (ja) | 2019-05-24 | 2022-08-10 | エンピリコ インク. | アンジオポエチン様7(angptl7)関連疾患の処置 |
| CN115397989A (zh) | 2020-02-18 | 2022-11-25 | 阿尔尼拉姆医药品有限公司 | 载脂蛋白C3(APOC3)iRNA组合物及其使用方法 |
| US20230190785A1 (en) * | 2020-03-30 | 2023-06-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
| WO2022072356A1 (en) * | 2020-09-29 | 2022-04-07 | Empirico Inc. | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases |
| GB202411150D0 (en) * | 2024-07-30 | 2024-09-11 | Res & Innovation Uk | Therapeutic antisense oligomers |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006102461A2 (en) * | 2005-03-22 | 2006-09-28 | Massachusetts Institute Of Technology | Influenza therapeutic |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067144B2 (en) * | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| CN100523215C (zh) * | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| DE10138912A1 (de) * | 2001-08-08 | 2003-02-27 | Medinnova Ges Med Innovationen | Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen |
| US20030219895A1 (en) * | 2002-05-22 | 2003-11-27 | Isis Pharmaceuticals Inc. | Antisense modulation of CDC-like kinase 1 expression |
| US20040242518A1 (en) * | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
| DE10313636A1 (de) * | 2003-03-26 | 2004-10-14 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Verwendung von Wirksubstanzen zur Vorbeuge oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen |
-
2007
- 2007-10-11 US US12/445,228 patent/US20110150897A1/en not_active Abandoned
- 2007-10-11 JP JP2009531778A patent/JP2010505897A/ja active Pending
- 2007-10-11 EP EP07818923A patent/EP2087110A2/en not_active Withdrawn
- 2007-10-11 AU AU2007306542A patent/AU2007306542B2/en not_active Ceased
- 2007-10-11 CA CA002666185A patent/CA2666185A1/en not_active Abandoned
- 2007-10-11 WO PCT/EP2007/008852 patent/WO2008043561A2/en not_active Ceased
- 2007-10-11 SG SG201007842-6A patent/SG166778A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006102461A2 (en) * | 2005-03-22 | 2006-09-28 | Massachusetts Institute Of Technology | Influenza therapeutic |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023549500A (ja) * | 2020-11-13 | 2023-11-27 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 凝固第V因子(F5)iRNA組成物およびその使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20110150897A1 (en) | 2011-06-23 |
| WO2008043561A3 (en) | 2008-10-02 |
| SG166778A1 (en) | 2010-12-29 |
| AU2007306542A1 (en) | 2008-04-17 |
| WO2008043561A2 (en) | 2008-04-17 |
| CA2666185A1 (en) | 2008-04-17 |
| EP2087110A2 (en) | 2009-08-12 |
| AU2007306542B2 (en) | 2013-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007306542B2 (en) | Influenza targets | |
| US20120282674A1 (en) | Method for the preparation of an influenza virus | |
| US8933046B2 (en) | Influenza targets | |
| Zhang et al. | Induction of the cellular miR-29c by influenza virus inhibits the innate immune response through protection of A20 mRNA | |
| Keshavarz et al. | miRNA-based strategy for modulation of influenza A virus infection | |
| KR20050084607A (ko) | 인플루엔자 치료제 | |
| Zhang et al. | p-STAT1 regulates the influenza A virus replication and inflammatory response in vitro and vivo | |
| Szabat et al. | RNA secondary structure as a first step for rational design of the oligonucleotides towards inhibition of influenza a virus replication | |
| Wu et al. | Inhibition of highly pathogenic avian H5N1 influenza virus replication by RNA oligonucleotides targeting NS1 gene | |
| Shen et al. | Altered viral replication and cell responses by inserting microRNA recognition element into PB1 in pandemic influenza A virus (H1N1) 2009 | |
| Wang et al. | Critical role of microRNAs in host and influenza A (H1N1) virus interactions | |
| Zavyalova et al. | Aptamers to hemagglutinin: A novel tool for influenza virus recognition and neutralization | |
| KR101839260B1 (ko) | 조류인플루엔자 바이러스 miRNA 및 이의 식별, 검출과 응용 | |
| Jang et al. | Molecular responses to the influenza A virus in chicken trachea-derived cells | |
| Azhar et al. | miRNAs in SARS-CoV-2 infection: an update | |
| CN101880677B (zh) | 针对2009新甲型流感病毒多聚酶基因和核蛋白基因的siRNA序列及其应用 | |
| Hartawan et al. | Improving siRNA design targeting nucleoprotein gene as antiviral against the Indonesian H5N1 virus | |
| EP3154579A1 (en) | New treatment against influenza virus | |
| CN108113995A (zh) | 微RNA hsa-mir-1-3p及其类似物的应用,和表达该微RNA载体的应用 | |
| Bamunuarachchi | The Role of Tankyrase in Host Antiviral Responses to Influenza Virus Infection | |
| CN103215345B (zh) | 抑制流感病毒复制的宿主相关基因及其筛选方法和应用 | |
| Saengchoowong | Enhanced propagation yield of influenza viruses for vaccine production through cellular microRNAs regulation | |
| CN116531494A (zh) | 一种CH25h在治疗H9N2亚型禽流感病毒感染药物中的应用 | |
| HK40004256A (en) | Compositions and methods for providing a prognosis for influenza infection | |
| Ward | Host Modulators of the Death Response to Influenza A Infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100906 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100906 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120801 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121030 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121106 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121129 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121206 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121228 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130110 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130125 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130909 |